Natural hormone therapy for menopause

References

• Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, et al Estogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–534.
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, et al Effect of estrogen plus progestin on stroke in postmenopausal women: the women's Health Initiative: a randomized trial. JAMA 2003;289:2673–2684.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cry MG, Thomson CA, et al Influence of estrogen plus progestin on breast cancer and mammography in healthy women: women's health initiative randomized trial. JAMA 2003;289:3243–3253.
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, et al Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–2662.
   PubMed Web of Science ®Google Scholar
• Lemon HM. Oestriol and prevention of breast cancer. Lancer 1973;10:546–547.
   Google Scholar
• Lemon HM. Pathophysiological considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl (copenh) 1980;233:17–27.
   PubMedGoogle Scholar
• Siiteri PK. Pregnancy hormone estriol may reduce risk for breast cancer. Doctor's Guide 2002, www.pslgroup.com.
   Google Scholar
• Vehkavaara S, Silveria A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H. Effects of oral and transdermal estrogen replacement therapy on markersof coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619–625.
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: effects ofcontinuouiscombination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4:42–48.
   PubMedGoogle Scholar
• Thijssen JH. Oestrogens, progestins and breast proliferation. Zentralbl Gynakol 1997;119(Suppl 2):43–47.
   PubMedGoogle Scholar
• Petrakis NL, Wrensch MR, Ernster VL, Miike R, Murai J, Simberg N, Siiteri PK. Influence of pregnancy and lactation on serum and breast fluid estrogen levels: implications for breast cancer risk. Int J Cancer 1987;40:587–591.
   PubMed Web of Science ®Google Scholar
• Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, et al Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 2000;95–112.
   Google Scholar
• Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effect on Bcl-2 and p53. Ann Clin Lab Sci 1998;28:360–369.
   PubMed Web of Science ®Google Scholar
• Formby B, Wiley TS. Bcl-2, surviving and variant CD44v7-v10 are down regulated and p53 upregulated in breast cancer cells by progesterone: inhibition of cell growth and apoptosis. Mol Cell Biochem 1999;202:53–61.
   PubMed Web of Science ®Google Scholar
• Zheng ZY, Zheng SM, Bay BH, Aw SE, Lin V C-L. Anti-estrogenic mechanism of unliganded progesterone receptor isoform B in breast cancer cells. Breast Cancer Res Treat 2008;110:111–125. Epub 2007 Aug 9.
   PubMed Web of Science ®Google Scholar
• Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer 1996;7312:1552–1555.
   Google Scholar
• Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360–1367.
   PubMed Web of Science ®Google Scholar
• Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints:arandomized, double-blind trial. Neurology 2007;69:1322–1330.
   PubMed Web of Science ®Google Scholar
• Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004;292:2243–2248.
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002;89(l):12E–18E.
   PubMedGoogle Scholar
• Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17-beta-Estradiol attenuates the acetycholine-induced coronary arterial constriction in women. Circulation 1995;92:5–8.
   PubMed Web of Science ®Google Scholar
• Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2031–2041.
   PubMedGoogle Scholar
• Hermsmeyer RK, Mishra RG, Pavcnik M, Uchida B, Axthelm MK, Stanczyk FZ, Burry KA, Illingworth DR, Kaski JC, Nordt FJ. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb Vasc Biol 2004;24:955–961.
   PubMed Web of Science ®Google Scholar
• Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P. Natural progesterone, but not Medroxyprogesterone, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:2154–2159.
   PubMed Web of Science ®Google Scholar
• Sorensen MB, Collins P, Ong PJ, Webb CM, Hayward CS, Asbury EA, Gatehouse PD, Elkington AG, Yang GZ, Kubba A, et al Long-term use of contraceptive depot Medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002;106:1646–1651.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–454.
   PubMed Web of Science ®Google Scholar
• Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11. Epub 2006 Feb 17.
   PubMed Web of Science ®Google Scholar